Cross-sectional and longitudinal assessments of risk factors associated with hypertension and moderately increased albuminuria comorbidity in patients with type 2 diabetes: a 9-year open cohort study.
comorbidity
hypertension
microalbuminuria
moderately increased albuminuria
risk factor
type 2 diabetes
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
10
2018
accepted:
21
05
2019
entrez:
15
8
2019
pubmed:
15
8
2019
medline:
15
8
2019
Statut:
epublish
Résumé
Moderately increased albuminuria (MIA) is strongly associated with hypertension (HTN) in patients with type 2 diabetic mellitus (T2DM). However, the association between risk factors and coexisting HTN and MIA remains unassessed. This study aimed to determine both cross-sectional and longitudinal associations of risk factors with HTN and MIA comorbidity in patients with T2DM. A total of 1,600 patients with T2DM were examined at baseline and longitudinal data were obtained from 1,337 T2DM patients with at least 2 follow-up visits to assess the presence of HTN alone (yes/no), MIA alone (yes/no) and the coexistence of both (yes/no) in a 9-year open cohort study between 2004 and 2013. Bivariate mixed-effects logistic regression with a Bayesian approach was employed to evaluate associations of risk factors with HTN and MIA comorbidity in the longitudinal assessment. After adjustment for age and BMI, patients with uncontrolled plasma glucose, as a combined index of the glucose profile, were more likely to have HTN [odds ratio (OR): 1.73 with 95% Bayesian credible intervals (BCI) 1.29-2.20] and MIA [OR: 1.34 (95% BCI 1.13-1.62)]. The risks of having HTN and MIA were increased by a one-year raise in diabetes duration [with 0.89 (95% BCI 0.84-0.96) and 0.81 (95% BCI 0.73-0.92) ORs, respectively] and a one-unit increase in non-high-density lipoprotein-cholesterol (Non-HDL-C) [with 1.30 (95% BCI 1.23-1.34) and 1.24 (95% BCI 1.14-1.33) ORs, respectively]. T2DM patients with HTN, MIA, and the coexistence of both had uncontrolled plasma glucose, significantly higher Non-HDL-C, and shorter diabetes duration than the other T2DM patients. Duration of diabetes and uncontrolled plasma glucose index showed the stronger effects on HTN and MIA comorbidity than on each condition separately.
Sections du résumé
BACKGROUND
BACKGROUND
Moderately increased albuminuria (MIA) is strongly associated with hypertension (HTN) in patients with type 2 diabetic mellitus (T2DM). However, the association between risk factors and coexisting HTN and MIA remains unassessed.
OBJECTIVES
OBJECTIVE
This study aimed to determine both cross-sectional and longitudinal associations of risk factors with HTN and MIA comorbidity in patients with T2DM.
METHODS
METHODS
A total of 1,600 patients with T2DM were examined at baseline and longitudinal data were obtained from 1,337 T2DM patients with at least 2 follow-up visits to assess the presence of HTN alone (yes/no), MIA alone (yes/no) and the coexistence of both (yes/no) in a 9-year open cohort study between 2004 and 2013. Bivariate mixed-effects logistic regression with a Bayesian approach was employed to evaluate associations of risk factors with HTN and MIA comorbidity in the longitudinal assessment.
RESULTS
RESULTS
After adjustment for age and BMI, patients with uncontrolled plasma glucose, as a combined index of the glucose profile, were more likely to have HTN [odds ratio (OR): 1.73 with 95% Bayesian credible intervals (BCI) 1.29-2.20] and MIA [OR: 1.34 (95% BCI 1.13-1.62)]. The risks of having HTN and MIA were increased by a one-year raise in diabetes duration [with 0.89 (95% BCI 0.84-0.96) and 0.81 (95% BCI 0.73-0.92) ORs, respectively] and a one-unit increase in non-high-density lipoprotein-cholesterol (Non-HDL-C) [with 1.30 (95% BCI 1.23-1.34) and 1.24 (95% BCI 1.14-1.33) ORs, respectively].
CONCLUSIONS
CONCLUSIONS
T2DM patients with HTN, MIA, and the coexistence of both had uncontrolled plasma glucose, significantly higher Non-HDL-C, and shorter diabetes duration than the other T2DM patients. Duration of diabetes and uncontrolled plasma glucose index showed the stronger effects on HTN and MIA comorbidity than on each condition separately.
Identifiants
pubmed: 31410041
doi: 10.2147/DMSO.S189726
pii: 189726
pmc: PMC6646050
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1123-1139Déclaration de conflit d'intérêts
The authors report no conflicts of interest in regard to this work.
Références
Hypertension. 1999 Jun;33(6):1392-8
pubmed: 10373222
Arch Intern Med. 2001 Sep 10;161(16):2000-5
pubmed: 11525702
J Am Soc Nephrol. 2002 Apr;13(4):1034-9
pubmed: 11912263
Diabetes Care. 1992 Jul;15(7):815-9
pubmed: 1516497
Diabetes Res Clin Pract. 2005 Oct;70(1):71-80
pubmed: 16126125
J Hypertens. 2007 Sep;25(9):1751-62
pubmed: 17762635
Am J Transplant. 2007 Dec;7(12):2748-56
pubmed: 17941956
Eur Heart J. 2007 Dec;28(24):3059-66
pubmed: 17981826
Rev Diabet Stud. 2007 Winter;4(4):242-8
pubmed: 18338078
Circulation. 2009 Jan 20;119(2):351-7
pubmed: 19095622
Pol Arch Med Wewn. 2009 Sep;119(9):533-40
pubmed: 19776697
Annu Rev Clin Psychol. 2010;6:79-107
pubmed: 20192796
Am J Ther. 2010 May-Jun;17(3):337-40
pubmed: 20479581
Diabetologia. 2012 Mar;55(3):636-43
pubmed: 22186981
Atherosclerosis. 2012 Jul;223(1):1-68
pubmed: 22698795
Int J Nephrol Renovasc Dis. 2013 Dec 21;7:13-24
pubmed: 24379690
Endocrinol Metab Clin North Am. 2014 Mar;43(1):103-22
pubmed: 24582094
Diabetes Metab J. 2014 Feb;38(1):51-7
pubmed: 24627828
Pak J Med Sci. 2014 May;30(3):511-4
pubmed: 24948969
Diabetologia. 2014 Dec;57(12):2465-74
pubmed: 25226881
Hypertension. 2014 Dec;64(6):1228-34
pubmed: 25245391
PLoS One. 2014 Oct 27;9(10):e109702
pubmed: 25347846
PLoS One. 2014 Dec 02;9(12):e112639
pubmed: 25461381
Stat Med. 2015 May 20;34(11):1876-88
pubmed: 25630757
World J Diabetes. 2015 Feb 15;6(1):17-29
pubmed: 25685275
Clin Diabetes. 2015 Apr;33(2):97-111
pubmed: 25897193
Arch Public Health. 2015 Sep 25;73:43
pubmed: 26413295
J Hum Hypertens. 2016 Sep;30(9):527-33
pubmed: 26674756
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Popul Health Manag. 2017 Feb;20(1):6-12
pubmed: 27124621
Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):504-12
pubmed: 27553599
Clin Epidemiol. 2017 Mar 31;9:195-204
pubmed: 28408854
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382